As part of the agreement, Astellas will pay an upfront payment of $50 million and has committed to up to $550 million in prospective development, sales and other contingent payments. Poseida will also be eligible to receive tiered, double-digit royalties on net sales. will complete the transaction through its subsidiary Xyphos Biosciences.
The collaboration aims to combine “each company’s state-of-the-art mobile treatment platforms,” according to Wednesday’s announcement.
Poseida will contribute its proprietary allogeneic CAR-T platform, while Xyphos will lend its ACCEL and convertibleCAR technologies. The purpose of the partnership is to produce a CAR-T construction, which in turn will result in two applicants for convertible CAR products for forgings. tumors.
Xyphos will reimburse Poseida for prices similar to the agreement and will take over R’s activities
Designed to be a flexible mobile therapy, Xyphos’ convertibleCAR generation uses a modified NKG2D protein, an herbal human receptor found in killer herbal mobiles and some T-mobiles, and works to aid in immune surveillance.
According to the biotech website, modifications to NKG2D make it possible to control and activate the convertibleCAR construct with modified molecules, such as bispecific antibodies, that can recognize binding sites in tumor cells. This technique brings tumor cells closer to immune cells that have turned to attack and destroy them.
In addition, attaching other functional fractions to the convertible CAR structure allows them to target other antigens, which can help treatments target tumor cells that have been detected through the immune system.
Adam Pearson, Astellas’ chief strategy officer, said in a statement that the partnership with Poseida “will bring synergies between the two corporations’ innovative studios and, in the end, will lead to the expansion of Astellas’ portfolio and the delivery of next-generation CAR-T mobile technology. “therapies. ” cancer patients.
Wednesday’s announcement follows an earlier agreement between the two companies, signed in August 2023, on Poseida paints in mobile cancer therapy. Astellas then invested $50 million in Poseida, part of which was used to acquire 8. 8% of Poseida’s shares, while the other party purchased exclusive marketing and preferential denial of licensing rights for the P-MUC1C-ALLO1 clinical-stage CAR-T program for falsified tumors.
Tristan Manalac is an independent scientist based in Metro Manila, Philippines. Connect with them on LinkedIn or email them at tristan@tristanmanalac. com or tristan. manalac@biospace. com.
Back to news